Cardiovascular Disease Doctors in Grand Forks, ND Accepting Medicare

6 Cardiovascular Disease doctors found. Showing 1 - 6

Abdelhamid M Ahmed, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1000 S Columbia Rd, Grand Forks, ND 58201 Phone: 701-780-6000

Mohamed Chebaclo, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 S Columbia Rd, Grand Forks, ND 58201 Phone: 701-780-5000

Stephen A Korte, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1300 S Columbia Rd, Grand Forks, ND 58201 Phone: 701-780-2300    Fax: 830-768-9254

Dr. Rabeea Aboufakher, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1300 S Columbia Rd - Altru 1300 Columbia, Grand Forks, ND 85201 Phone: 701-780-2300    Fax: 701-780-1942

Noah N Chelliah, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1191 South Columbia Road, Grand Forks, ND 58201 Phone: 701-780-2000    Fax: 701-746-1663

Dr. Puvanalingam Ayyadurai, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1300 S Columbia Rd, Grand Forks, ND 58201 Phone: 701-780-2300

News Archive

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association (ADA), showing that this investigational compound, a dipeptidyl peptidase (DPP)-4 inhibitor, achieved significant, sustained and clinically meaningful reductions in blood glucose as measured by haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) concentrations.(1-6) Linagliptin is being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes.

PAREXEL to present key trends in late phase development and Comparative Effectiveness Research

Experts from PAREXEL International Corporation, a leading global biopharmaceutical services provider, will address key trends in late phase development and Comparative Effectiveness Research at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual European Congress, to be held from October 24 - 27, 2009 in Paris, France.

Interventions for Pediatricians only partially successful

Continuing medical education, newsletters and resource guides were only partially successful in changing the way that pediatricians handled behavioral health problems, according to a follow-up study at Wake Forest University School of Medicine.

Administration proposes additional funding for FDA for fiscal year (FY) 2009

HHS Secretary Leavitt today announced that the Administration is amending its budget request for fiscal year (FY) 2009 to include an additional $275 million for the U.S. Food and Drug Administration (FDA). He called on Congress to act quickly on this budget amendment and pending Administration legislative proposals to strengthen FDA.

Pharmacy group ASHP opposes proposed cuts to Medicare payment rates for drugs

Proposed cuts to the Medicare payment rates for drugs that hospitals acquire under the 340B Drug Pricing Program, if enacted, could have devastating consequences for the low-income and uninsured patients that receive care from the nation's safety net hospitals, according to ASHP.

Read more Medical News

› Verified 6 days ago